Quick Facts

• Condition Managed: Intermittent Claudication
• Core Benefit: Supports an increase in walking distance
• Therapeutic Focus: Addressing symptoms of reduced blood flow in the legs

Cilostazol Mylan is a prescription medication utilized for the management of symptoms associated with intermittent claudication. This condition is caused by peripheral arterial disease (PAD) and involves pain, cramping, or weakness in the legs that occurs during physical activity, such as walking, and typically resolves with rest.

The main therapeutic benefit of this medication is to help increase the distance a patient can walk without experiencing discomfort. It is typically considered a second-line option for patients whose symptoms have not sufficiently improved after implementing lifestyle changes, including supervised exercise programs and smoking cessation.

By supporting improved circulation and reducing the aggregation of platelets, this treatment may help alleviate the pain experienced in the lower limbs during walking.

Who can and cannot use Cilostazol Mylan?

Cilostazol Mylan is officially approved for use in adults who have Intermittent Claudication, but only after prior lifestyle changes like exercise and smoking cessation have failed to provide adequate benefit. Eligibility is strictly defined by regulatory documents, which list numerous absolute exclusions.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated (prohibited) in patients with heart failure of any severity, as stated by the FDA and EMA. Use is also prohibited in individuals with a known predisposition to bleeding, including active peptic ulceration, recent hemorrhagic stroke (within six months), or poorly controlled hypertension. Further absolute contraindications include severe renal impairment (creatinine clearance le 25 ml/min) and moderate or severe hepatic impairment.

Eligibility Restrictions and Limitations

The medicine is contraindicated in patients who have had a myocardial infarction or coronary intervention within the last six months, or those with certain severe tachyarrhythmias. It is also prohibited for those taking two or more antiplatelet or anticoagulant agents concurrently. Use is not recommended in pregnant or breastfeeding women. Safety and efficacy have not been established in the pediatric population, while no special dosage requirements are noted for older adults.

Interactions with other medicines and products

Official regulatory information identifies specific combinations and substances that significantly impact the safe use of Cilostazol Mylan, primarily through additive effects on blood clotting or changes in drug concentration (exposure).

Interaction Type	Practical Constraint
Pharmacodynamic (PD)	Co-administration is formally contraindicated with two or more additional antiplatelet or anticoagulant medicines (e.g., clopidogrel, warfarin, apixaban) due to the risk of increased bleeding.
Pharmacokinetic (PK)	Combining the product with strong or moderate inhibitors of CYP3A4 or CYP2C19 enzymes (e.g., ketoconazole, omeprazole) increases drug exposure and requires close regulatory management.

---

Food, Substances, and Administration Timing

The absorption of Cilostazol Mylan is significantly increased by food, especially high-fat meals. To ensure consistent control of drug exposure, the product must be taken on an empty stomach, meaning at least 30 minutes before or 2 hours after a meal. Consumption of grapefruit juice is also restricted due to its effect on increasing drug concentration.

Furthermore, the regulatory profile includes specific cautions: use is formally contraindicated in patients with severe renal impairment or moderate to severe hepatic impairment, as these conditions alter the clearance of the drug and its metabolites.

Dual Modulation of the cAMP Signaling Pathway

Cilostazol Mylan's primary mechanism involves the selective, reversible inhibition of the Phosphodiesterase type 3 (PDE3) enzyme, predominantly in vascular smooth muscle and platelets. Blocking this enzyme prevents the breakdown of the signaling molecule cyclic Adenosine Monophosphate (cAMP), leading to a sustained increase in its intracellular concentration inside the target cells. This elevation of cAMP is the central molecular step that initiates the drug's physiological effects.

---

Mechanism of Arterial Vasodilation and Increased Perfusion

The elevated cAMP levels in vascular smooth muscle cells (VSMCs) trigger an intracellular cascade that causes the muscle cells to relax. This physiological change results in the widening of arterial blood vessels (vasodilation), which directly lowers resistance to flow and increases the volume of blood delivered to peripheral tissues. This action modifies the vascular muscle tone, leading to lowered peripheral vascular resistance.

---

Antiplatelet Action for Reduced Cellular Adhesiveness

Concurrently, the increase in cAMP within platelets interferes with the molecular signals required for them to become activated and clump together (aggregate). This effect leads to reduced platelet stickiness and adhesion, resulting in blood exhibiting reduced cellular adhesiveness. The combined effect of vasodilation and reduced platelet aggregability increases flow volume and facilitates tissue perfusion.

Cilostazol Mylan is utilized exclusively through oral administration as a tablet, available in 50 mg and 100 mg strengths. The standard adult regimen requires a dose of 100 mg taken twice daily. This twice-daily pattern establishes a continuous administration schedule. To ensure appropriate systemic exposure, the tablet must be consumed on an empty stomach. This means taking the medicine either at least 30 minutes before a meal or 2 hours after both breakfast and dinner.

A specific dose adjustment is mandated when the medicine is used concurrently with strong or moderate inhibitors of the CYP3A4 or CYP2C19 enzymes. In this procedural condition, the dose is reduced to 50 mg twice daily. No specialized dosage adjustments are required for older adult patients or those with mild hepatic or renal function impairment.

The treatment follows a duration-dependent protocol. While symptomatic improvement may begin to be observed as early as two to four weeks, the full therapeutic effect may require up to 12 weeks of continuous use. The course of therapy must be assessed for symptomatic improvement after 3 months. If sufficient change is not realized within this period, discontinuation is generally indicated. If a dose is missed, the patient is instructed to skip the administration and proceed with the next regularly scheduled dose; doubling the dose is not the specified procedure for missed timing.

Research evidence / Overview of studies for Cilostazol Mylan

Evidence for use in Intermittent Claudication

This section will summarize the structure of the clinical evaluation, focusing primarily on the design of the placebo-controlled trials and systematic reviews that measured functional walking distances and patient-reported quality of life measures.

The research base for intermittent claudication includes Randomized Controlled Trials (RCTs). These studies employed double-blind RCTs that involved comparing the medicine against a placebo. Research was conducted using adult populations diagnosed with stable, chronic intermittent claudication. The research examined outcomes related to physical discomfort by measuring changes in walking distance on a standardized treadmill test, including Pain-Free Walking Distance (PFWD) and Maximum Walking Distance (MWD). Researchers also explored patient-reported outcomes related to daily functioning and general Health-Related Quality of Life (HQL).

Studies report patterns related to measured changes in symptoms observed during the study period. Findings describe patterns observed in the functional outcomes, with research exploring short-term symptom changes in measured walking distances. Evidence also contributes to understanding symptom patterns related to the physical discomfort of the legs. However, findings were mixed across studies regarding the consistency and magnitude of changes measured in the various patient-reported Quality of Life metrics.

---

Long-term Research and Extended Follow-up

This section will outline the scope of studies conducted over longer observation periods, including trials designed to evaluate all-cause mortality and other major cardiovascular events, and what is known about the durability of measured functional outcomes.

Beyond the initial short-term efficacy research, studies monitored patients over extended follow-up periods to assess long-term patterns related to the body and vascular health. This research focused on the occurrence of major clinical outcomes, such as all-cause mortality, the risk of having a stroke or myocardial infarction (heart attack), and the need for revascularization procedures or amputation. While these long-term studies observed patterns related to major events, the data are still emerging and certainty remains low.

---

What Remains Uncertain and Research Gaps

The available research provides context but also highlights areas where data are still emerging or where the evidence is limited. One key limitation is the lack of long-term data to definitively characterize the impact of Cilostazol Mylan on serious clinical outcomes, such as the risk of stroke, amputation, or all-cause mortality. Furthermore, findings were mixed regarding the consistency of patient-reported outcomes describing perceived discomfort and general quality of life. The evidence quality varies across studies, and research for certain subgroups or those with complex vascular issues remains insufficient, indicating that research is ongoing to fill these identified gaps.

Common questions about Cilostazol Mylan (FAQ)

---

Q: Does Cilostazol Mylan affect blood pressure?

A: Official documents note that the medicine's mechanism involves arterial vasodilation, which is the widening of blood vessels. As a result of this action, low blood pressure, known as hypotension, is listed in regulatory information as a common side effect of the medicine.

Q: Can Cilostazol Mylan interact with medicines used for stomach acid (like PPIs or antacids)?

A: Co-administration with strong or moderate inhibitors of certain enzymes, such as CYP2C19, is known to increase the concentration of the medicine in the body. Since some stomach acid reducers belong to this class of inhibitors, this interaction is a factor described in official prescribing information that influences appropriate use.

Q: Does taking Cilostazol Mylan require any special monitoring or tests?

A: Regulatory information documents the need for periodic monitoring of the body's blood counts (hematology). This monitoring is documented in official regulatory information due to the risk of rare, but serious, adverse blood reactions such as aplastic anemia.

Q: Can Cilostazol Mylan affect my liver function?

A: Regulatory data lists adverse reactions related to the liver, including reports of hepatic dysfunction or abnormal liver function tests. Furthermore, its use is officially restricted (contraindicated) in patients with moderate to severe pre-existing liver impairment.

Q: Does this medicine interact with blood pressure lowering drugs?

A: Because the medicine works by widening blood vessels (vasodilation) and is documented to commonly cause low blood pressure (hypotension), using it at the same time as other blood pressure-lowering drugs is a factor that may necessitate caution, as the effect could be additive.

Q: Can Cilostazol Mylan be taken by people with diabetes?

A: Official eligibility information does not list diabetes as a condition that restricts the use of the medicine. However, its use is officially restricted (contraindicated) in patients with specific conditions, such as congestive heart failure, regardless of whether they have diabetes.

Q: Does this medicine affect my ability to drive?

A: Official product information notes that common side effects such as dizziness and headache may affect attention or coordination. Official documents state that caution is necessary when operating machinery or driving.

Q: Can Cilostazol Mylan affect my sleep?

A: Regulatory documents list insomnia (difficulty sleeping) as an adverse reaction that has been reported by patients using the medicine.

Q: Is Cilostazol Mylan known to cause weight changes?

A: The product label notes that peripheral edema (swelling or fluid retention) is a common side effect of the medicine. This fluid retention can sometimes be associated with changes in a person's body weight.

Q: Will Cilostazol Mylan help with pain in my hands or feet?

A: The medicine is indicated solely for improving symptoms of intermittent claudication, which is a condition involving discomfort, pain, or cramping that occurs in the legs during exercise. Its approved use does not extend to pain in the hands or feet.

Q: Why does the packaging say this medicine is a phosphodiesterase inhibitor?

A: The term describes the drug's primary mechanism. It works by temporarily blocking the action of the Phosphodiesterase type 3 (PDE3) enzyme in the body. This mechanism increases a signaling molecule called cAMP, which ultimately leads to blood vessel widening and reduced stickiness of blood cells.

Q: Does Cilostazol Mylan help with restless legs syndrome?

A: Official product information indicates that the drug is approved solely for the treatment of intermittent claudication. It is not formally indicated or approved for restless legs syndrome.

Q: Why do doctors check for bleeding problems before prescribing Cilostazol Mylan?

A: The medicine is an antiplatelet agent, meaning it reduces the stickiness of blood cells. Therefore, its use is officially restricted (contraindicated) in patients who are actively experiencing pathological bleeding, which is the reason its use is restricted in patients with active pathological bleeding.

Q: Are there any specific foods that should be avoided while taking this medication?

A: Regulatory documents specify that grapefruit juice is restricted due to its effect on increasing the drug's concentration in the body. The medicine must also be taken on an empty stomach (at least 30 minutes before or 2 hours after a meal) as food significantly increases its absorption.

Q: Are there official reports about allergic reactions to Cilostazol Mylan?

A: Yes, official documents list severe immune system disorders among the rare reported adverse reactions. These reactions include hypersensitivity, angioedema (swelling beneath the skin), and anaphylaxis.

Q: Can Cilostazol Mylan make my legs feel warm or tingly?

A: The medicine's action of widening blood vessels (vasodilation) may result in changes in sensation. Official documents list hot flushes as a reported adverse reaction.

Q: Is Cilostazol Mylan used for preventative reasons?

A: The drug is described in clinical research as a treatment for the symptoms of stable, chronic intermittent claudication once the condition is present. It is not formally indicated for preventing the development of the underlying disease.

Q: Can women who are pregnant or breastfeeding use Cilostazol Mylan?

A: Use of this medicine is formally contraindicated in women who are pregnant or breastfeeding. This restriction is because the safety of the medicine in these specific populations has not been established according to official regulatory information.

Q: Are there any official studies showing the long-term effects of Cilostazol Mylan?

A: Studies have monitored patients over extended follow-up periods to assess long-term patterns related to the body and vascular health. However, official documents note that the available data regarding certain major clinical outcomes are still emerging and certainty remains low.

Official Storage and Disposal Instructions

Scope Element	Official Regulatory Requirement
Storage Temperature	Controlled Room Temperature (20 C to 25 C); excursions permitted to 15 C–30 C.
Protection	Store away from excess heat and moisture and protect from freezing or light.
Packaging Rules	Must be kept in the original container, which should be kept tightly closed.
Child Safety	Keep the medicine out of the sight and reach of children and away from accessible locations.
Disposal Rules	Do not dispose of unused or expired tablets in wastewater or household trash.

The official labeling defines that the tablets must be stored securely at room temperature to preserve product quality, explicitly prohibiting freezing and exposure to moisture. Disposal instructions require that the product be discarded according to local pharmaceutical waste regulations, and patients must consult a pharmacist for proper disposal, ensuring the medicine is removed after its expiration date.